Galapagos NV Company Description

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV

Country	Belgium
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	1,123
CEO	Paulus Stoffels

Contact Details

Address: Generaal De Wittelaan L11 A3 Mechelen, 2800 Belgium
Phone	32 1 534 29 00
Website	glpg.com

Stock Details

Ticker Symbol	GLPG
Exchange	Euronext Amsterdam
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	BE0003818359
SIC Code	2836

Key Executives

Name	Position
Dr. Paulus A. Stoffels M.D., Ph.D.	Chief Executive Officer, Chairman, Interim Head of Research & Development
Sofie Van Gijsel	Head of Investor Relations
Valeria Cnossen	Executive Vice President and General Counsel
Marieke Vermeersch	Head of Corporate Communication
Annelies Missotten	Executive Vice President and Chief Human Resources Officer
Ellen Van Der Aar	Head of Development
Philippe Alen M.B.A., Ph.D., Pharm.D.	Senior Vice President and Head of Business Development
Alice Dietrich	Head of Medical Affairs
Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D.	Head of Small Molecules Discovery and Senior Vice President
Patrik Ringblom	Head of Strategy and US Lead